Please ensure Javascript is enabled for purposes of website accessibility
Final Phase of COVID Vaccine Trials is Here. CA Volunteers Needed.
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
July 15, 2020

Share

Moderna is targeting July 27 to begin phase 3 testing of their COVID-19 vaccine. The company is looking for thousands of volunteers to participate.

The Cambridge, Massachusetts-based biotech company is the first to announce an estimated start date for phase 3 trials in the United States.

Newly released data from earlier human trials showed their vaccine candidate appears to be safe and provide some immunity. The most commonly reported systemic adverse events following second vaccination at the 100 microgram dose were fatigue (80%), chills (80%), headache (60%), and myalgia (53%), all of which were moderate in severity. The most common local adverse event at the 100 microgram dose was pain at the injection site (100%), which was also transient and mild or moderate in severity.

(Moderna Facebook)

New data from early trials shows Moderna’s COVID-19 vaccine candidate appears to be safe and provide some immunity.

Guidance for Vaccine Volunteers

Information about the trial, including guidance for vaccine volunteers, was posted on clinicaltrials.gov on Tuesday.

A brief summary posted on the site says, “The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.”

Moderna describes mRNA as like software for the cell; mRNA medicines are sets of instructions. And these instructions direct cells in the body to make proteins to prevent or fight disease.

Below is a video Moderna posted to its Facebook page describing the use of mRNA therapeutics.

For inclusion in the study, volunteers must meet several criteria including the following:

  • Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written informed consent.
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non-childbearing potential may be enrolled in the study.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:
    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1).
    • Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through three months following the second dose on Day 29.
    • Is not breastfeeding.
  • Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through three months after the second dose.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the three months before enrollment.

Moderna tweeted information and a link about the study Tuesday.

California Study Locations

Several locations throughout California will be utilized and volunteers will be needed for each.

  • Advanced Clinical Research, Rancho Paseo in Banning
  • University of California San Diego in La Jolla
  • eStudySite in La Mesa
  • UCLA Vine Street Clinic CRS  in Los Angeles
  • Paradigm Clinical Research Institute Inc. in Redding
  • Benchmark Research in Sacramento
  • Medical Center For Clinical Research, M3 Wake Research in San Diego

If you are interested, contact Moderna Clinical Trials at (855) 663-6762 or email clinicaltrials@modernatx.com

The randomized, placebo-controlled trial is expected to include approximately 30,000 participants at the 100 microgram dose level in the U.S.

Early Results Encouraging

Moderna’s experimental vaccine against the coronavirus showed encouraging results in early testing.

COVID-19 antibodies were found in all 45 participants, the biotech company announced in a May news release.

Neal Browning of Bothell, Washington, spoke to GV Wire via Zoom shortly after the early testing results were made public.

“I’m the second person to receive the vaccine in a small dose so that means I’ve got the antibodies,” Browning said. “One of the first people to reach out to me was Jennifer Haller, the lady who was the first to receive the vaccine. She was super excited, too. We chatted a little bit on text about that.”

Neal Browning becomes the second volunteer to receive the investigational COVID-19 vaccine in the NIH-supported clinical trial in Seattle. (AP File)

Moderna said the early vaccine data indicated that it provided full protection against viral replication in the lungs in a mouse challenge model.

An interim analysis just published in The New England Journal of Medicine shows mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2.

In a press release, Moderna says, “After two vaccinations, mRNA-1273 elicited robust neutralizing antibody titers. At Day 43, neutralizing activity against SARS-CoV-2 was seen in all evaluated participants.”

Moderna has posted a video of a conference call on Wednesday providing more information to investors.

500 Million Doses a Year

Moderna is working closely with Operation Warp Speed and the NIH, including NIAID’s COVID-19 Prevention Trials Network to conduct the Phase 3 study.

With the Phase 3 dose being finalized at 100 micrograms, the company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company’s internal U.S. manufacturing site and strategic collaboration with Lonza.

In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. On July 9, Moderna announced a collaboration with ROVI for large-scale, commercial fill-finish manufacturing of mRNA-1273 intended in principle to supply markets outside of the U.S. starting in early 2021 at ROVI’s facility in Madrid, Spain.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

DON'T MISS

Higher Taxes on Millionaires? Trump Says He’s Open, but Many in His Party Are Not

DON'T MISS

Ex-US Rep. George Santos Sentenced to Over 7 Years in Prison for Fraud and Identity Theft

DON'T MISS

Selma Mayor Charged With Electioneering Violation on Election Day

DON'T MISS

Fresno Air Improves. Where Does It Rank in the US?

DON'T MISS

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

DON'T MISS

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

DON'T MISS

Conflicting US-China Talks Statements Add to Global Trade Confusion

DON'T MISS

Driving Near the Fresno Airport Next Week? Plan for Road Closures

DON'T MISS

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

UP NEXT

Fresno Air Improves. Where Does It Rank in the US?

UP NEXT

Conflicting US-China Talks Statements Add to Global Trade Confusion

UP NEXT

California’s Economy Ranks Fourth Worldwide, Surpasses Japan

UP NEXT

Exclusive: US Congress Republicans Seek $27 Billion for Golden Dome in Trump Tax Bill

UP NEXT

China Exempts Some Goods From US Tariffs

UP NEXT

Why Texas Is Ahead of California on Bilingual Education

UP NEXT

Abundance Meets Resistance: Are CA Dems Finally Ready to Go All In on Building Housing?

UP NEXT

Less Than Half of Californians Think K-12 Schools Are on the Right Track: Poll

UP NEXT

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

UP NEXT

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

Selma Mayor Charged With Electioneering Violation on Election Day

1 hour ago

Fresno Air Improves. Where Does It Rank in the US?

2 hours ago

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

2 hours ago

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

3 hours ago

Conflicting US-China Talks Statements Add to Global Trade Confusion

3 hours ago

Driving Near the Fresno Airport Next Week? Plan for Road Closures

3 hours ago

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

4 hours ago

Fresno Police Arrest 17 in Domestic Violence Crackdown

4 hours ago

What’s Next for Fresno Smoke Shop Ordinance: Lawsuit, Veto, Override?

5 hours ago

Visalia Man Sentenced to Life in Prison for 2019 Fatal Stabbing

5 hours ago

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

LOS ANGELES — California regulators have released a new proposal to allow the testing of self-driving heavy duty trucks on public roads. The...

58 minutes ago

58 minutes ago

California Proposes Allowing Testing of Self-Driving Heavy-Duty Trucks

1 hour ago

Higher Taxes on Millionaires? Trump Says He’s Open, but Many in His Party Are Not

1 hour ago

Ex-US Rep. George Santos Sentenced to Over 7 Years in Prison for Fraud and Identity Theft

Selma Mayor Scott Robertson (left) has been charged with misdemeanor electioneering for allegedly campaigning near voters at a polling place during the November 2024 election. (Facebook)
1 hour ago

Selma Mayor Charged With Electioneering Violation on Election Day

2 hours ago

Fresno Air Improves. Where Does It Rank in the US?

2 hours ago

As Harris Ponders Run for CA Governor, Is She Prepared for the Daunting Job?

3 hours ago

Stocks Rise With Tech-Related Shares, Notch Weekly Gains; Dollar Up

A drone view shows containers at the terminals at the port in Kwai Chung in Hong Kong, China, April 3, 2025. (REUTERS/Tyrone Siu/File Photo)
3 hours ago

Conflicting US-China Talks Statements Add to Global Trade Confusion

Help continue the work that gets you the news that matters most.

Search

Send this to a friend